MMF Rewind | CTI's Next Chapter: A Conversation with Jon Koch and Brian Lawrence

This week, we're revisiting a previous conversation with Jon Koch, CEO, and Brian Lawrence, CFO and President, as they share their perspective on what’s next for CTI as the organization enters a new phase of growth. They reflect on CTI’s legacy of partnership and execution while outlining how they plan to expand its impact across complex clinical trials.From scaling capabilities and investing in talent to strengthening operational discipline and embracing data-driven decision-making, Jon and Brian offer an inside look at how leadership alignment is shaping strategy. They also explore the evolving demands of the clinical research industry, from the need for predictability and site support to the practical application of technology and AI.At its core, this conversation is about balancing growth with purpose: delivering for sponsors, strengthening teams, and ultimately improving outcomes for patients.00:36 CTI Rewind: Revisiting CTI's leadership transition and future vision00:58 Expanding CTI's reach in complex and advanced therapy trials02:23 Disciplined growth strategy and sustainable global expansion04:38 CTI's legacy of care, credibility, and partnership06:14 Driving performance through metrics and accountability09:03 Leadership alignment and partnership in action12:13 Talent development, infrastructure, and AI enablement14:14 Positioning CTI for continued growth in complex trials17:12 Key industry trends: predictability, sites, and technology20:40 Sustaining culture and employee experience22:08 Long-term vision: scale, impact, and global presence25:15 Closing takeaways: quality, people, and execution